Logo image of NGNE

NEUROGENE INC (NGNE) Stock Price, Quote, News and Overview

NASDAQ:NGNE - Nasdaq - US64135M1053 - Common Stock - Currency: USD

18.74  +1.08 (+6.12%)

After market: 18.74 0 (0%)

NGNE Quote, Performance and Key Statistics

NEUROGENE INC

NASDAQ:NGNE (5/29/2025, 8:00:01 PM)

After market: 18.74 0 (0%)

18.74

+1.08 (+6.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High74.49
52 Week Low6.88
Market Cap267.23M
Shares14.26M
Float12.95M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07/bmo
IPO03-07 2014-03-07


NGNE short term performance overview.The bars show the price performance of NGNE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

NGNE long term performance overview.The bars show the price performance of NGNE in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of NGNE is 18.74 USD. In the past month the price increased by 24.93%. In the past year, price decreased by -50.16%.

NEUROGENE INC / NGNE Daily stock chart

NGNE Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.07 327.88B
AMGN AMGEN INC 13.66 152.46B
GILD GILEAD SCIENCES INC 14.36 138.21B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.81B
REGN REGENERON PHARMACEUTICALS 13.66 65.36B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.19B
ARGX ARGENX SE - ADR 98.97 35.47B
ONC BEONE MEDICINES LTD-ADR 6.31 26.67B
BNTX BIONTECH SE-ADR N/A 24.10B
NTRA NATERA INC N/A 21.58B
SMMT SUMMIT THERAPEUTICS INC N/A 19.47B
BIIB BIOGEN INC 8.39 19.45B

About NGNE

Company Profile

NGNE logo image Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 107 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.

Company Info

NEUROGENE INC

535 W 24Th Street, 5Th Floor

New York City NEW YORK US

Employees: 107

NGNE Company Website

NGNE Investor Relations

Phone: 18772375020

NEUROGENE INC / NGNE FAQ

What is the stock price of NEUROGENE INC today?

The current stock price of NGNE is 18.74 USD. The price increased by 6.12% in the last trading session.


What is the ticker symbol for NEUROGENE INC stock?

The exchange symbol of NEUROGENE INC is NGNE and it is listed on the Nasdaq exchange.


On which exchange is NGNE stock listed?

NGNE stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEUROGENE INC stock?

13 analysts have analysed NGNE and the average price target is 45.29 USD. This implies a price increase of 141.66% is expected in the next year compared to the current price of 18.74. Check the NEUROGENE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEUROGENE INC worth?

NEUROGENE INC (NGNE) has a market capitalization of 267.23M USD. This makes NGNE a Micro Cap stock.


How many employees does NEUROGENE INC have?

NEUROGENE INC (NGNE) currently has 107 employees.


What are the support and resistance levels for NEUROGENE INC (NGNE) stock?

NEUROGENE INC (NGNE) has a support level at 17.28 and a resistance level at 19.08. Check the full technical report for a detailed analysis of NGNE support and resistance levels.


Is NEUROGENE INC (NGNE) expected to grow?

The Revenue of NEUROGENE INC (NGNE) is expected to decline by -100% in the next year. Check the estimates tab for more information on the NGNE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEUROGENE INC (NGNE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEUROGENE INC (NGNE) stock pay dividends?

NGNE does not pay a dividend.


When does NEUROGENE INC (NGNE) report earnings?

NEUROGENE INC (NGNE) will report earnings on 2025-08-07, before the market open.


What is the Price/Earnings (PE) ratio of NEUROGENE INC (NGNE)?

NEUROGENE INC (NGNE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.35).


What is the Short Interest ratio of NEUROGENE INC (NGNE) stock?

The outstanding short interest for NEUROGENE INC (NGNE) is 23.18% of its float. Check the ownership tab for more information on the NGNE short interest.


NGNE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to NGNE. When comparing the yearly performance of all stocks, NGNE is a bad performer in the overall market: 83.81% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

NGNE Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to NGNE. The financial health of NGNE is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NGNE Financial Highlights

Over the last trailing twelve months NGNE reported a non-GAAP Earnings per Share(EPS) of -4.35. The EPS decreased by -51.24% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -22.38%
ROE -24.21%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-8%
Sales Q2Q%N/A
EPS 1Y (TTM)-51.24%
Revenue 1Y (TTM)N/A

NGNE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 88% to NGNE. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of -13.67% and a revenue growth -100% for NGNE


Ownership
Inst Owners109.15%
Ins Owners9.04%
Short Float %23.18%
Short Ratio10.19
Analysts
Analysts87.69
Price Target45.29 (141.68%)
EPS Next Y-13.67%
Revenue Next Year-100%